GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic ...

Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent ...

Altimmune has a mixed earnings surprise history, beating estimates in three of the trailing four quarters and missing the ...

Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors ...

Altimmune's pemvidutide showed strong MASH resolution and good tolerability in IMPACT, but fibrosis data fell short. See why ALT stock is downgraded to hold.

If you suffered purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly ...

On June 26, 2025, Altimmune issued a press release announcing "topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH)." ...

Key Obesity companies such as 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group ...